According to related industries, Handok Teva has begun negotiations with the HIRA on the drug price of Ajovy, a target migraine treatment for Calcitoningenene-related peptide (CGRP). Ajovy passed the HIRA Drug Benefit Evaluation Committee last month.
Ajovy's drug price is expected to be negotiated as its competitive drug and first item, Emgality, was applied in September. If Ajovy succeeds in registering, competition for the prescription of the two drugs is expected to begin in earnest. Emgality and Ajovy are the same category of drugs, but there are differences in dosage, so they are being selected according to the characteristics of severe migraine patients.

Emgality is administered 240 mg (two